Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 488

1.

Pluripotent Stem Cell Platforms for Drug Discovery.

Chen KG, Mallon BS, Park K, Robey PG, McKay RDG, Gottesman MM, Zheng W.

Trends Mol Med. 2018 Jul 10. pii: S1471-4914(18)30136-9. doi: 10.1016/j.molmed.2018.06.009. [Epub ahead of print] Review.

PMID:
30006147
2.

Revisiting the role of ABC transporters in multidrug-resistant cancer.

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM.

Nat Rev Cancer. 2018 Jul;18(7):452-464. doi: 10.1038/s41568-018-0005-8. Review.

PMID:
29643473
3.

Structures of the Multidrug Transporter P-glycoprotein Reveal Asymmetric ATP Binding and the Mechanism of Polyspecificity.

Esser L, Zhou F, Pluchino KM, Shiloach J, Ma J, Tang WK, Gutierrez C, Zhang A, Shukla S, Madigan JP, Zhou T, Kwong PD, Ambudkar SV, Gottesman MM, Xia D.

J Biol Chem. 2017 Jan 13;292(2):446-461. doi: 10.1074/jbc.M116.755884. Epub 2016 Nov 18.

4.

Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.

Bahr JC, Robey RW, Luchenko V, Basseville A, Chakraborty AR, Kozlowski H, Pauly GT, Patel P, Schneider JP, Gottesman MM, Bates SE.

Oncotarget. 2016 Oct 25;7(43):69804-69815. doi: 10.18632/oncotarget.12001.

5.

An automated method measures variability in P-glycoprotein and ABCG2 densities across brain regions and brain matter.

Kannan P, Schain M, Kretzschmar WW, Weidner L, Mitsios N, Gulyás B, Blom H, Gottesman MM, Innis RB, Hall MD, Mulder J.

J Cereb Blood Flow Metab. 2017 Jun;37(6):2062-2075. doi: 10.1177/0271678X16660984. Epub 2016 Jan 1.

6.

In Vivo Bioluminescent Imaging of ATP-Binding Cassette Transporter-Mediated Efflux at the Blood-Brain Barrier.

Bakhsheshian J, Wei BR, Hall MD, Simpson RM, Gottesman MM.

Methods Mol Biol. 2016;1461:227-39. doi: 10.1007/978-1-4939-3813-1_19.

PMID:
27424909
7.

Outcomes From the NIH Clinical Research Training Program: A Mentored Research Experience to Enhance Career Development of Clinician-Scientists.

Ognibene FP, Gallin JI, Baum BJ, Wyatt RG, Gottesman MM.

Acad Med. 2016 Dec;91(12):1684-1690. doi: 10.1097/ACM.0000000000001245.

8.

(18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.

Liow JS, Zoghbi SS, Hu S, Hall MD, Hines CS, Shetty HU, Araneta MD, Page EM, Pike VW, Kreisl WC, Herscovitch P, Gottesman MM, Theodore WH, Innis RB.

Neuroimage. 2016 Sep;138:134-140. doi: 10.1016/j.neuroimage.2016.05.045. Epub 2016 May 19.

9.

Cryo-EM Analysis of the Conformational Landscape of Human P-glycoprotein (ABCB1) During its Catalytic Cycle.

Frank GA, Shukla S, Rao P, Borgnia MJ, Bartesaghi A, Merk A, Mobin A, Esser L, Earl LA, Gottesman MM, Xia D, Ambudkar SV, Subramaniam S.

Mol Pharmacol. 2016 Jul;90(1):35-41. doi: 10.1124/mol.116.104190. Epub 2016 May 11.

10.

The Drug Excipient Cyclodextrin Interacts With d-Luciferin and Interferes With Bioluminescence Imaging.

Kumar JS, Miller Jenkins LM, Gottesman MM, Hall MD.

Mol Imaging. 2016 Jan 27;15. pii: 1536012115625225. doi: 10.1177/1536012115625225. Print 2016.

11.

Basic science: Bedrock of progress.

Collins FS, Anderson JM, Austin CP, Battey JF, Birnbaum LS, Briggs JP, Clayton JA, Cuthbert B, Eisinger RW, Fauci AS, Gallin JI, Gibbons GH, Glass RI, Gottesman MM, Gray PA, Green ED, Greider FB, Hodes R, Hudson KL, Humphreys B, Katz SI, Koob GF, Koroshetz WJ, Lauer MS, Lorsch JR, Lowy DR, McGowan JJ, Murray DM, Nakamura R, Norris A, Perez-Stable EJ, Pettigrew RI, Riley WT, Rodgers GP, Sieving PA, Somerman MJ, Spong CY, Tabak LA, Volkow ND, Wilder EL.

Science. 2016 Mar 25;351(6280):1405. doi: 10.1126/science.351.6280.1405-a. No abstract available.

12.

Mathematical Modeling Reveals That Changes to Local Cell Density Dynamically Modulate Baseline Variations in Cell Growth and Drug Response.

Greene JM, Levy D, Herrada SP, Gottesman MM, Lavi O.

Cancer Res. 2016 May 15;76(10):2882-90. doi: 10.1158/0008-5472.CAN-15-3232. Epub 2016 Mar 1.

13.

Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier.

Kumar JS, Wei BR, Madigan JP, Simpson RM, Hall MD, Gottesman MM.

Sci Rep. 2016 Feb 8;6:20418. doi: 10.1038/srep20418.

14.

Human-Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P-Glycoprotein (ABCB1).

Pluchino KM, Hall MD, Moen JK, Chufan EE, Fetsch PA, Shukla S, Gill DR, Hyde SC, Xia D, Ambudkar SV, Gottesman MM.

Biochemistry. 2016 Feb 23;55(7):1010-23. doi: 10.1021/acs.biochem.5b01064. Epub 2016 Feb 10.

15.

A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy.

Gillet JP, Andersen JB, Madigan JP, Varma S, Bagni RK, Powell K, Burgan WE, Wu CP, Calcagno AM, Ambudkar SV, Thorgeirsson SS, Gottesman MM.

Mol Pharmacol. 2016 Feb;89(2):263-72. doi: 10.1124/mol.115.101360. Epub 2015 Dec 14.

16.

Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein.

Weidner LD, Fung KL, Kannan P, Moen JK, Kumar JS, Mulder J, Innis RB, Gottesman MM, Hall MD.

Drug Metab Dispos. 2016 Feb;44(2):275-82. doi: 10.1124/dmd.115.067785. Epub 2015 Dec 10.

17.

Using the BacMam Baculovirus System to Study Expression and Function of Recombinant Efflux Drug Transporters in Polarized Epithelial Cell Monolayers.

Fung KL, Kapoor K, Pixley JN, Talbert DJ, Kwit AD, Ambudkar SV, Gottesman MM.

Drug Metab Dispos. 2016 Feb;44(2):180-8. doi: 10.1124/dmd.115.066506. Epub 2015 Nov 30. Erratum in: Drug Metab Dispos. 2016 Apr;44(4):517.

18.

Toward a Better Understanding of the Complexity of Cancer Drug Resistance.

Gottesman MM, Lavi O, Hall MD, Gillet JP.

Annu Rev Pharmacol Toxicol. 2016;56:85-102. doi: 10.1146/annurev-pharmtox-010715-103111. Epub 2015 Oct 28. Review.

PMID:
26514196
19.

Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs.

Jagodinsky JC, Sulima A, Cao Y, Poprawski JE, Blackman BN, Lloyd JR, Swenson RE, Gottesman MM, Hall MD.

J Biol Inorg Chem. 2015 Oct;20(7):1081-95. doi: 10.1007/s00775-015-1290-2. Epub 2015 Sep 1.

20.

Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA.

Pluchino KM, Esposito D, Moen JK, Hall MD, Madigan JP, Shukla S, Procter LV, Wall VE, Schneider TD, Pringle I, Ambudkar SV, Gill DR, Hyde SC, Gottesman MM.

PLoS One. 2015 Aug 26;10(8):e0136396. doi: 10.1371/journal.pone.0136396. eCollection 2015.

21.

The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene.

Gottesman MM, Pastan IH.

J Natl Cancer Inst. 2015 Aug 18;107(9). pii: djv222. doi: 10.1093/jnci/djv222. Print 2015 Sep. No abstract available.

22.

The Inhibitor Ko143 Is Not Specific for ABCG2.

Weidner LD, Zoghbi SS, Lu S, Shukla S, Ambudkar SV, Pike VW, Mulder J, Gottesman MM, Innis RB, Hall MD.

J Pharmacol Exp Ther. 2015 Sep;354(3):384-93. doi: 10.1124/jpet.115.225482. Epub 2015 Jul 6.

23.

Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.

Souza PS, Madigan JP, Gillet JP, Kapoor K, Ambudkar SV, Maia RC, Gottesman MM, Fung KL.

Exp Cell Res. 2015 Aug 15;336(2):318-28. doi: 10.1016/j.yexcr.2015.06.005. Epub 2015 Jun 19.

24.

Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.

Stukova M, Hall MD, Tsotsoros SD, Madigan JP, Farrell NP, Gottesman MM.

J Inorg Biochem. 2015 Aug;149:45-8. doi: 10.1016/j.jinorgbio.2015.05.003. Epub 2015 May 14.

25.

Beyond 3D culture models of cancer.

Tanner K, Gottesman MM.

Sci Transl Med. 2015 Apr 15;7(283):283ps9. doi: 10.1126/scitranslmed.3009367. Review.

26.

The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans.

Zheng M, Zhang H, Dill DL, Clark JD, Tu S, Yablonovitch AL, Tan MH, Zhang R, Rujescu D, Wu M, Tessarollo L, Vieira W, Gottesman MM, Deng S, Eberlin LS, Zare RN, Billard JM, Gillet JP, Li JB, Peltz G.

PLoS Med. 2015 Feb 3;12(2):e1001782. doi: 10.1371/journal.pmed.1001782. eCollection 2015 Feb.

27.

Modeling intrinsic heterogeneity and growth of cancer cells.

Greene JM, Levy D, Fung KL, Souza PS, Gottesman MM, Lavi O.

J Theor Biol. 2015 Feb 21;367:262-277. doi: 10.1016/j.jtbi.2014.11.017. Epub 2014 Nov 29.

28.

Lost in Translation: Regulation of ABCG2 Expression in Human Embryonic Stem Cells.

Padmanabhan R, Chen KG, Gottesman MM.

J Stem Cell Res Ther. 2014 Mar 17;4. pii: 24230.

29.

Gil ashwell, 1916-2014.

Gottesman MM, Hanover JA, Jakoby W.

Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16232-3. doi: 10.1073/pnas.1417238111. Epub 2014 Nov 10. No abstract available.

30.

The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.

Chang KE, Wei BR, Madigan JP, Hall MD, Simpson RM, Zhuang Z, Gottesman MM.

Mol Cancer Ther. 2015 Jan;14(1):90-100. doi: 10.1158/1535-7163.MCT-14-0496. Epub 2014 Nov 5.

31.

Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5.

Keniya MV, Holmes AR, Niimi M, Lamping E, Gillet JP, Gottesman MM, Cannon RD.

Mol Pharm. 2014 Oct 6;11(10):3452-62. doi: 10.1021/mp500230b. Epub 2014 Aug 22.

32.

Network features suggest new hepatocellular carcinoma treatment strategies.

Lavi O, Skinner J, Gottesman MM.

BMC Syst Biol. 2014 Jul 29;8:88. doi: 10.1186/s12918-014-0088-0.

33.

Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tiopronin.

Hall MD, Marshall TS, Kwit AD, Miller Jenkins LM, Dulcey AE, Madigan JP, Pluchino KM, Goldsborough AS, Brimacombe KR, Griffiths GL, Gottesman MM.

J Biol Chem. 2014 Aug 1;289(31):21473-89. doi: 10.1074/jbc.M114.581702. Epub 2014 Jun 14.

34.

Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes.

Hall MD, Telma KA, Chang KE, Lee TD, Madigan JP, Lloyd JR, Goldlust IS, Hoeschele JD, Gottesman MM.

Cancer Res. 2014 Jul 15;74(14):3913-22. doi: 10.1158/0008-5472.CAN-14-0247. Epub 2014 May 8.

35.

Uptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306.

Fung KL, Tepede AK, Pluchino KM, Pouliot LM, Pixley JN, Hall MD, Gottesman MM.

Mol Pharm. 2014 Aug 4;11(8):2692-702. doi: 10.1021/mp500114e. Epub 2014 Jun 17.

36.

Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.

Szakács G, Hall MD, Gottesman MM, Boumendjel A, Kachadourian R, Day BJ, Baubichon-Cortay H, Di Pietro A.

Chem Rev. 2014 Jun 11;114(11):5753-74. doi: 10.1021/cr4006236. Epub 2014 Apr 23. Review. No abstract available.

37.

SCORHE: a novel and practical approach to video monitoring of laboratory mice housed in vivarium cage racks.

Salem GH, Dennis JU, Krynitsky J, Garmendia-Cedillos M, Swaroop K, Malley JD, Pajevic S, Abuhatzira L, Bustin M, Gillet JP, Gottesman MM, Mitchell JB, Pohida TJ.

Behav Res Methods. 2015 Mar;47(1):235-50. doi: 10.3758/s13428-014-0451-5.

38.

The impact of cell density and mutations in a model of multidrug resistance in solid tumors.

Greene J, Lavi O, Gottesman MM, Levy D.

Bull Math Biol. 2014 Mar;76(3):627-53. doi: 10.1007/s11538-014-9936-8. Epub 2014 Feb 20.

39.

Simplifying the complexity of resistance heterogeneity in metastasis.

Lavi O, Greene JM, Levy D, Gottesman MM.

Trends Mol Med. 2014 Mar;20(3):129-36. doi: 10.1016/j.molmed.2013.12.005. Epub 2014 Jan 31.

40.

MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer.

Fung KL, Pan J, Ohnuma S, Lund PE, Pixley JN, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM.

Cancer Res. 2014 Jan 15;74(2):598-608. doi: 10.1158/0008-5472.CAN-13-2064. Epub 2013 Dec 4.

41.

Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.

Bakhsheshian J, Wei BR, Chang KE, Shukla S, Ambudkar SV, Simpson RM, Gottesman MM, Hall MD.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20801-6. doi: 10.1073/pnas.1312159110. Epub 2013 Dec 2.

42.

Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Xue X, Hall MD, Zhang Q, Wang PC, Gottesman MM, Liang XJ.

ACS Nano. 2013 Dec 23;7(12):10452-64. doi: 10.1021/nn405004f. Epub 2013 Dec 10. Review.

43.

The role of cell density and intratumoral heterogeneity in multidrug resistance.

Lavi O, Greene JM, Levy D, Gottesman MM.

Cancer Res. 2013 Dec 15;73(24):7168-75. doi: 10.1158/0008-5472.CAN-13-1768. Epub 2013 Oct 25.

44.

Microfabricated polymeric vessel mimetics for 3-D cancer cell culture.

Jaeger AA, Das CK, Morgan NY, Pursley RH, McQueen PG, Hall MD, Pohida TJ, Gottesman MM.

Biomaterials. 2013 Nov;34(33):8301-13. doi: 10.1016/j.biomaterials.2013.07.013. Epub 2013 Jul 30.

45.

Overlapping substrate and inhibitor specificity of human and murine ABCG2.

Bakhsheshian J, Hall MD, Robey RW, Herrmann MA, Chen JQ, Bates SE, Gottesman MM.

Drug Metab Dispos. 2013 Oct;41(10):1805-12. doi: 10.1124/dmd.113.053140. Epub 2013 Jul 18.

46.

P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway.

Galski H, Oved-Gelber T, Simanovsky M, Lazarovici P, Gottesman MM, Nagler A.

Biochem Pharmacol. 2013 Sep 1;86(5):584-96. doi: 10.1016/j.bcp.2013.06.004. Epub 2013 Jun 14. Erratum in: Biochem Pharmacol. 2014 Dec 1;92(3):518.

47.

The role of the NIH in nurturing clinician-scientists.

Gottesman MM.

N Engl J Med. 2013 Jun 13;368(24):2249-51. doi: 10.1056/NEJMp1302969. Epub 2013 May 15. No abstract available.

48.

Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.

Patel C, Stenke L, Varma S, Lindberg ML, Björkholm M, Sjöberg J, Viktorsson K, Lewensohn R, Landgren O, Gottesman MM, Gillet JP.

Cancer. 2013 Aug 15;119(16):3076-83. doi: 10.1002/cncr.28098. Epub 2013 May 14.

49.

Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier.

Kannan P, Pike VW, Halldin C, Langer O, Gottesman MM, Innis RB, Hall MD.

Mol Pharm. 2013 Jun 3;10(6):2222-9. doi: 10.1021/mp400011g. Epub 2013 May 2.

50.

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.

Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet JP, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE.

Blood. 2013 May 16;121(20):4115-25. doi: 10.1182/blood-2012-08-449140. Epub 2013 Mar 26.

Supplemental Content

Loading ...
Support Center